PE/VC  Athyrium Capital Management

http://www.athyrium.com





     Office Locations:

126 East 56th Street, Floor 4
New York, NY 10022
Phone: 212-402-6925

 

Stages:

  • Expansion
  • Growth
  • Middle Market


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Athyrium is a specialized asset management company which advises funds with over $3.2 billion in committed capital. Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations. Athyrium focuses on investment opportunities in the global healthcare sector broadly defined to include pharmaceuticals, biologics, biotechnology, specialty and generic pharmaceuticals, medical devices and products, laboratory and diagnostics products and services, healthcare services, and healthcare information technology. In general, Athyrium: seeks to invest $25 million to $150 million per transaction with the ability to scale-up opportunistically on select investments; invests in both public and select private companies across all geographies; and prefers to invest in commercial-stage companies that sell products that have highly compelling clinical data and are cost effective.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or New York Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Andrew Hyman Chief Operating Officer and General Counsel
    Hondo Sen Partner
    Jeffrey Ferrell Founder & Managing Hermouet
    Jeremy Lack Partner
    Laurent Hermouet Partner

     

    Portfolio companies include:


      BioFire Diagnostics
        web link


      Ironwood Pharmaceuticals
        web link


      MedPro Safety Products
        web link


      Stemline Therapeutics
        web link


      Syncardia Systems
        web link


      Verenium
        web link


     

    Recent News: